Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Patient characteristics: PET positive vs. PET negative

From: Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy

Characteristic PET positive PET negative
Number 92 37
Age (years) at PSMA PET (median, range) 72 (49–86) 72 (47–80)
Gleason Score [pts]
 6 8 (8.7%) 3 (8.1%)
 7a 19 (20.7%) 8 (21.6%)
 7b 23 (25.0%) 14 (37.8%)
 8 13 (14.1%) 5 (13.5%)
 9 27 (29.3%) 7 (18.9%)
 10 2 (2.2%)
Risk group (D’Amico) [pts]
 low 3 (3.3%) 2 (5.4%)
 intermediate 14 (15.2%) 7 (18.9%)
 high 75 (81.5%) 28 (75.7%)
PSA PRE-PSMA PET [ng/ml] (median/mean, range) 1.90/8.27 (0.14–150.0) 0.30/0.50 (0.13–3.24)
PSA doubling time
  ≤ 10 months 56 (77.8%) 25 (67.6%)
  > 10 months 16 (22.2%) 12 (32.4%)
ADT at time of PET [pts] 12 (13.0%) 2 (5.4%)
Activity of 68Ga-PSMA-HBED-CC [MBq] (mean, range) 191.96 (87–293) 186.78 (94–293)
  1. (Pts patients, PSA prostate specific antigen, ADT androgen deprivation therapy, MBq Mega-Becquerel)